Cadrenal Therapeutics, Inc. Cash and Cash Equivalents
Cadrenal Therapeutics, Inc. (CVKD) had Cash and Cash Equivalents of $2.39 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $2.39M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $2.31M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $4.01M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $3.86M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $2.39M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.31M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $4.01M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $3.86M 10-Q · filed 2025-11-10 | |
| 2025-08-06 | $5.00M 10-Q · filed 2025-08-11 | |
| 2025-06-30 | $5.57M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $7.34M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $10.02M 10-K · filed 2026-03-31 | $10.00M 10-K · filed 2025-03-13 |
| 2024-09-30 | $4.36M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $5.04M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $6.57M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $8.40M 10-Q · filed 2024-05-09 | |
| 2023-09-30 | $9.11M 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $32.59K 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |